Bio-IT World News
YouTube Facebook LinkedIn TwitterInstagram rss
a-divisiion-of-chi
  • Subscribe
  • News
    • Latest News
    • View Press Releases
    • Post a Press Release
    • Reprint Articles
  • Podcast
  • Advertise
    • Media Kit
    • Digital Advertising
    • Lead Generation
    • Editorial Calendar
    • Webinars
    • Whitepapers
    • Podcasts
    • View Press Releases
    • Post a Press Release
  • Free Downloads
    • Whitepapers
    • Podcasts
    • Webinars
    • Inside eBooks
  • Events
    • Webinars
    • Industry Events
    • IT Conferences
    • Bio-IT World Expo
    • Bio-IT World Expo Europe
  • About Us
    • Editorial Profile
    • Editorial Calender
    • Contact Us
    • Submit a story
    • Innovative Practices Awards
    • Linking Policy
  • Bio-IT World Expo
    • Bio-IT World Boston
    • Bio-IT World Europe
 
 
 
 
  • New Cell & Gene Therapy Solutions from Form Bio Analyze Billions of Potential Construct Candidates, Reducing Time-to-Clinic

    Sep 15, 2023, 07:23 AM by
    Form Bio, the provider of advanced computational life sciences technology announced today capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates. With great progress to date but headwinds around safety and manufacturability, Form’s new solutions help therapy developers find the safest and highest yielding versions of their therapies.
    Full story
  • Huateng Pharma to Attend CPHI Barcelona 2023

    Sep 15, 2023, 07:23 AM by
    Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.
    Full story
  • Cross-Department Collaboration Reveals Business Intelligence Already On Hand

    Sep 14, 2023, 01:00 AM by User Not Found
    Bio-IT World | INNOVATIVE PRACTICES AWARDS—There are questions every research group could ask. At Regeneron’s Research and Preclinical department, tackling these questions meant accounting for more than 2,000 expensive and space-constrained instruments and seeking insight into how they are used.
    Full story
  • COVID Vaccine Developers May Want To Pivot To Symptom Prevention

    Sep 13, 2023, 01:00 AM by User Not Found
    Bio-IT World | Vaccine developers may want to consider designing formulations intended to prevent symptoms rather than infection, which the COVID-19 pandemic has demonstrated can be hard to do with any long-lasting effect.
    Full story
  • Launch of high-quality (pre-clinical) enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutics

    Sep 12, 2023, 17:42 PM by
    Takara Bio Europe has announced the launch of new high-quality grade mRNA production enzymes suitable for pre-clinical and process development in mRNA vaccine and therapeutic manufacturing.
    Full story
  • Lonza Upgrades MODA-ES® Module for Enhanced Electronic Batch Record Execution

    Sep 12, 2023, 09:44 AM by
    Lonza has released the MODA-ES® Module v4.0, an upgrade to its electronic batch record (EBR) module that enhances user experience and simplifies integration to expedite product release.
    Full story
  • Study Finds Breast Cancer Spreads During Sleep, Highlights Role Of Hormones

    Sep 12, 2023, 01:00 AM by User Not Found
    Bio-IT World | The recent discovery that the metastatic spread of breast cancer accelerates during sleep sparked a lively conversation at last month’s Next Generation Dx Summit about new paths of exploration for thwarting a deadly pan-cancer process claiming 12 lives worldwide every minute.
    Full story
  • GenNext & SCIEX to Co-Market an Advanced High Order Structure Analysis (HOS) Workflow for Biopharmaceutical Research

    Sep 11, 2023, 08:49 AM by
    GenNext & SCIEX Co-Market an advanced high order structure analysis workflow for biopharmaceutical research to spread the adoption of the latest HOS and Mass Spec technologies to help scientists improve the safety, stability, and effectiveness of biotherapeutics
    Full story
  • GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting

    Sep 11, 2023, 08:49 AM by
    GenNext Unveils the World’s First Fully Automated Protein Footprinting System at the California Separation Science Society Meeting The new AutoFox™ System promises to deliver hands-free, high-throughput Hydroxyl Radical Protein Footprinting for sophisticated Higher Order Structural (HOS) analysis
    Full story
  • AVIA’s National Generative AI Collaborative Announces New Experts, Enhanced Health System Participation

    Sep 8, 2023, 09:00 AM by
    The Generative AI Strategic Collaborative reveals a slate of 10 clinical, ethics, technology, and regulatory experts for its national consortium
    Full story
  • BioIVT Completes XenoTech Integration, Highlights Expanded ADME-Tox Research Services at the North American ISSX Meeting

    Sep 8, 2023, 09:00 AM by
    BioIVT has implemented new tiered ‘fit-for-purpose’ study designs for metabolism, drug-drug interaction, and transporter programs, which utilize their electronic notebook system and automated reports, enabling them to better meet clients’ needs by reducing turnaround time, while maintaining the highest level of scientific expertise and quality.
    Full story
  • Amerigo Scientific Releases FSB Solution Products to Expedite Alzheimer’s Disease Research

    Sep 8, 2023, 09:00 AM by
    Full story
  • Scaling R&D Drug Discovery: The Future Of Lab Automation

    Sep 8, 2023, 01:00 AM by User Not Found
    Bio-IT World | In the coming decades, many of the grand challenges that society faces, from global food shortages to disease control and climate change, has the opportunity to be solved by biology. To achieve this, we must enable researchers within the biotech and healthcare ecosystems to be more productive than ever by improving scale, reproducibility, and accessibility.
    Full story
  • Intellegens and CPI awarded £1.6m Innovate UK grant to advance manufacture of oligonucleotide therapeutics with machine learning

    Sep 7, 2023, 08:19 AM by
    Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, part of UK Research and Innovation (UKRI), to apply ML in the emerging field of oligonucleotide therapies. In collaboration with the Centre for Process Innovation (CPI), the two-year project will augment and validate the company’s ML technology, Alchemite™, as a tool to enhance productivity and yields of oligonucleotide therapeutic manufacture through performance prediction and optimisation of quality control strategies.
    Full story
  • Lactabico graduates from German Accelerator to bring novel peptide-based drugs to the global market

    Sep 7, 2023, 08:19 AM by
    Lactabico, an innovative biotech startup, has announced its graduation from the prestigious German Accelerator, a leading institution dedicated to propelling the growth of startups in the biotechnology sector.
    Full story
  • Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy

    Sep 6, 2023, 14:45 PM by
    About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com About Ahead Therapeutics Ahead Therapeutics is a start-up biotech company that uses proprietary technology to develop treatments for different autoimmune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. These liposomes can induce antigen-specific immune tolerance through a biomimetic process, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. For more information, please visit www.aheadtherapeutics.com Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com
    Full story
  • Illumina Names Jacob Thaysen of Agilent New CEO

    Sep 5, 2023, 13:47 PM by User Not Found
    Bio-IT World | Illumina today announced that its Board of Directors has appointed Jacob Thaysen, Ph.D., senior vice president of Agilent Technologies and president of its Life Sciences and Applied Markets Group, as Illumina’s next Chief Executive Officer, effective September 25, 2023.
    Full story
  • Novel Biomarker Tracks Tightly With Tau Tangles In Alzheimer’s Disease

    Sep 5, 2023, 01:00 AM by User Not Found
    Bio-IT World | Researchers in the U.S. and Sweden have identified a biomarker (MTBR-tau243) for Alzheimer’s disease that tracks with the amount of damaging tau tangles in the brain and, when combined with a specific phosphorylated tau species (p-tau205), is nearly as predictive of cognitive function as tau-positron emission tomography (tau-PET) imaging.
    Full story
  • Nanopore News from Oxford Nanopore, University of Missouri, New Genedata Product, More

    Aug 31, 2023, 01:00 AM by User Not Found
    Bio-IT World | University of Missouri researchers developed an innovative method using nanopores; Oxford Nanopore speeds basecalling for MinKNOW; Standigm and Nashville Biosciences partner on early drug discovery research, and more.
    Full story
  • Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’

    Aug 30, 2023, 09:06 AM by
    National Initiative to Educate Patients, Drive Awareness, & Raise Funds for ZERO Prostate Cancer; Donation Made for Every Fact Sheet Downloaded at PSAonPSA.com
    Full story
  • «
  • 71
  • 72
  • 73
  • 74
  • 75 (current)
  • 76
  • 77
  • 78
  • 79
  • 80
  • »
 
CHI | Cambridge HealthTech Institute

250 First Avenue, Suite 300
Needham, MA 02494

P: 781.972.5400
F: 781.972.5425
E: chi@healthtech.com

Life Science Portals

Biological Therapeutic Products

Biomarkers & Diagnostics

Biopharma Strategy

Bioprocess & Manufacturing

Chemistry

Clinical Trials &
Translational Medicine

Drug & Device Safety

Drug Discovery & Development

Drug Targets

Healthcare

IT, AI, ML & Informatics

Technology & Tools For
Life Science

Therapeutic Indications

Venture, Innovation & Partnering

CHI Divisions

Conferences

Reports & Market Research

Barnett Educational Services

News & Advertising

Professional Services

Corporate Information

Cambridge Innovation
Institute

Executive Team

Testimonials

Mailing List

Careers


Request Information

Privacy Policy